AlphAIAlphAI — Financial news for AI agents
investing.comOCT 141 min read$ONCY

Oncolytics reports GOBLET study enrollment complete

Oncolytics Biotech (NASDAQ:ONCY) completed enrollment in its GOBLET Phase 1/2 study and expects final grant payment this quarter. Cohort 4 results are due in Q4 2026, with Cohort 5 results in H1 2027. The study, conducted in Germany, focuses on pelareorep-based therapies for cancer. The company plans to use data to guide future strategies. Pelareorep has Fast Track designation for colorectal, anal, and pancreatic cancer.

Original reporting
investing.com
Published Oct 14, 2026, 1:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 1:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$ONCY
Bullish
medium confidence
Mentioned
$ONCY
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ONCYBullishLow
01

Why it matters

The completion of enrollment reduces execution risk and sets the stage for data releases in Q4 2026 and H1 2027, which could drive stock movement.

02

Market read

Trial progress news is a typical catalyst for small‑cap biotech stocks, offering modest trading interest.

03

What to watch

Potential delays in data read‑out timelines or regulatory feedback could temper enthusiasm.

Relevance 7/10Novelty 7/10Timing: today

Background

Oncolytics Biotech (NASDAQ:ONCY) is developing pelareorep, an oncolytic virus, and has Fast Track designation for several cancers.

Company-level read

Ticker impact

$ONCYBullishMedium confidence
Context

Oncolytics Biotech announced today that enrollment in its GOBLET Phase 1/2 study is complete, a first‑report disclosure of trial progress.

Expected impact

modest upside as investors price in the upcoming cohort results

Evidence & confidence

The news is new and material for a biotech, but no immediate revenue or regulatory milestone is disclosed.

Market effects

Sector

May lift sentiment for oncolytic virus developers and other early‑stage oncology biotech peers.

Regional

Limited to U.S. biotech sector; no broader regional effect.

Global

Minor, confined to niche oncology trial space.

Counterpoint

What could challenge this read

Investors may view enrollment completion as a routine step without guaranteeing positive data, keeping the stock risk‑on.

Key entities

  • company
    Oncolytics Biotech Inc.

    Biotech firm developing oncolytic virus therapies.

  • organization
    Pancreatic Cancer Action Network

    Grant provider for the GOBLET study.

Read at source← All news

StoryOncolytics completes GOBLET enrollment and schedules upcoming data readouts

Related articles

OCT 14
$ONCYLow

Oncolytics Updates GOBLET Study Data Timelines, Expects Final PanCAN Grant Payment

Oncolytics Biotech (ONCY) updated its GOBLET study timelines, expecting final PanCAN grant payment in Q4 2026. Cohort 4 data is due in Q4 2026, with Cohort 5 results in H1 2027. Median overall survival in Cohort 4 exceeded expectations, and the company is winding down study infrastructure while monitoring remaining patients. ONCY is developing pelareorep for gastrointestinal cancers and is currently trading at $0.55, up 13.72%.

rttnews.com2 min
OCT 14
$ONCYMed

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

Global cancer drug spending reached $252B in 2024 and is forecast to exceed $400B by 2028, with the U.S. accounting for 46%. Several companies, including Oncolytics Biotech (ONCY), Revolution Medicines (RVMD), Eli Lilly (LLY), Genmab (GMAB), and Exelixis (EXEL), are advancing treatments for colorectal and pancreatic cancers. Oncolytics reported accelerating enrollment in a colorectal cancer study, while Revolution Medicines received FDA approval for a pancreatic cancer drug.

prnewswire.com3 min
SEP 30
$ONCYMedAI 8/10

Oncolytics Highlights Pelareorep Preclinical Findings In Hepatocellular Carcinoma

Oncolytics Biotech (ONCY) reported preclinical findings in PNAS showing pelareorep treatment may alter the tumor microenvironment in liver cancer, increasing PD-L1 and ICOSL levels, and CD8+ T-cell density. The company noted liver cancer is not a target indication but is studying pelareorep in colorectal cancer with an interim update expected by year-end 2026. ONCY stock closed at $0.67, down 2.05% in premarket.

rttnews.com2 min
SEP 29
$ONCYMedAI 8/10

Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Oncolytics Biotech ® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy Data support pelareorep’s potential as a backbone therapy to transform immunologically inactive liver tumors into a phenotype

SEC EDGAR 8-K2 min
SEP 29
$ONCYMedAI 8/10

Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy

Oncolytics Biotech (Nasdaq: ONCY) announced data published in the Proceedings of the National Academy of Sciences showing pelareorep can alter the tumor microenvironment in liver cancer, making it susceptible to immunotherapy. The study demonstrated increased PD-L1 expression, ICOSL levels, and CD8+ T cell density. Oncolytics is developing pelareorep for metastatic gastrointestinal cancers and is pursuing strategic partnerships.

globenewswire.com2 min